Argentina Study Supports Ivermectin for COVID-19

Argentina Study Supports Ivermectin for COVID-19

Argentina’s largest newspaper, Clarin, reported on September 23 about positive results in an ivermectin study, including reduced viral loads, in a study conducted in that nation. Clarin posits that this, “is the first scientific evidence available in the world, which manages to verify the effect of this drug on the coronavirus under in vivo conditions in infected patients.” The results were reported Wednesday from the Ministry of Science and Technology, and followed a four-month effort; the work was conducted by a public-private consortium being led by Alejandro Krolewiecki of the Tropical Diseases Research Institute. Scientists explained that the 0.6 mg/kg dose was three times the amount “usually used." They said this dose, "produces the fastest and most profound elimination of the virus when treatment is started in the early stages of infection (up to 5 days from the onset of symptoms)."

Awaited Verification Arrives

Studies started in May, after the consortium was chosen for funding. About 6 million pesos was awarded. Testing was done with 45 patients with moderate or mild COVID-19. 30 got the high-dose ivermectin, and the remainder were controls. "Those who received the d...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee